Literature DB >> 17126006

Use of recombinant activated factor VII in massive obstetric haemorrhage.

J Haynes1, M Laffan, F Plaat.   

Abstract

Massive obstetric haemorrhage is a life-threatening emergency that remains a major cause of maternal mortality. Conventional management is aimed at optimising uterine tone, replacing circulating volume and blood products, and surgery to achieve haemostasis. Recently there have been numerous reports of the (unlicensed) use of recombinant activated factor VII in the management of major obstetric haemorrhage. We report our experience of using it in the treatment of major post-partum haemorrhage in four previously healthy parturients. The published reports of recombinant activated factor VII use in post-partum haemorrhage (unrelated to pre-existing coagulopathies) are compared.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126006     DOI: 10.1016/j.ijoa.2006.07.005

Source DB:  PubMed          Journal:  Int J Obstet Anesth        ISSN: 0959-289X            Impact factor:   2.603


  3 in total

1.  Recombinant Factor VIIa in Post-partum Hemorrhage: A New Weapon in Obstetrician's Armamentarium.

Authors:  Navneet Magon; Km Babu
Journal:  N Am J Med Sci       Date:  2012-04

Review 2.  Recombinant activated factor VII in post partum haemorrhage.

Authors:  Navneet Magon; K M Babu; Krishan Kapur; Sanjiv Chopra; Gurdarshan Singh Joneja
Journal:  Niger Med J       Date:  2013-09

3.  Recombinant human activated factor VII in postpartum hemorrhagic shock: the dark side.

Authors:  E J W van Veen; W E Monteban-Kooistra; J H J M Meertens; J J M Ligtenberg; J E Tulleken; J G Zijlstra
Journal:  Intensive Care Med       Date:  2007-08-01       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.